UA112488C2 - Три(гетеро)арилпіразоли і їх застосування - Google Patents

Три(гетеро)арилпіразоли і їх застосування

Info

Publication number
UA112488C2
UA112488C2 UAA201502210A UAA201502210A UA112488C2 UA 112488 C2 UA112488 C2 UA 112488C2 UA A201502210 A UAA201502210 A UA A201502210A UA A201502210 A UAA201502210 A UA A201502210A UA 112488 C2 UA112488 C2 UA 112488C2
Authority
UA
Ukraine
Prior art keywords
hetero
arilpyrazoles
applications
diseases
prevention
Prior art date
Application number
UAA201502210A
Other languages
English (en)
Inventor
Штеффен Вільдум
Буркхард Кленке
Астрід Вендт
Original Assignee
Айкуріс Гмбх & Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48986151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA112488(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Айкуріс Гмбх & Ко. Кг filed Critical Айкуріс Гмбх & Ко. Кг
Publication of UA112488C2 publication Critical patent/UA112488C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В заявці описані нові три(гетеро)арилпіразоли, способи їх одержання, їх застосування для лікування і/або попередження захворювань, а також їх застосування для приготування лікарських засобів, призначених для лікування і/або попередження захворювань, краще ретровірусних захворювань, у людей і/або тварин.
UAA201502210A 2012-08-17 2013-08-16 Три(гетеро)арилпіразоли і їх застосування UA112488C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012016908.6A DE102012016908A1 (de) 2012-08-17 2012-08-17 Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
PCT/EP2013/067201 WO2014027112A1 (de) 2012-08-17 2013-08-16 Tris-(hetero)aryl-pyrazole und ihre verwendung

Publications (1)

Publication Number Publication Date
UA112488C2 true UA112488C2 (uk) 2016-09-12

Family

ID=48986151

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201502210A UA112488C2 (uk) 2012-08-17 2013-08-16 Три(гетеро)арилпіразоли і їх застосування

Country Status (27)

Country Link
US (1) US9249148B2 (uk)
EP (1) EP2885300A1 (uk)
JP (1) JP2015524835A (uk)
KR (1) KR20150042841A (uk)
CN (1) CN104684913B (uk)
AP (1) AP2015008325A0 (uk)
AR (1) AR092145A1 (uk)
AU (1) AU2013303993A1 (uk)
BR (1) BR112015003115A2 (uk)
CA (1) CA2881997A1 (uk)
CL (1) CL2015000362A1 (uk)
CU (1) CU20150015A7 (uk)
DE (1) DE102012016908A1 (uk)
EA (1) EA201500232A1 (uk)
HK (1) HK1212327A1 (uk)
IL (1) IL237298A0 (uk)
MA (1) MA37928A1 (uk)
MX (1) MX2015002046A (uk)
NZ (1) NZ704727A (uk)
PE (1) PE20150869A1 (uk)
PH (1) PH12015500322B1 (uk)
SG (1) SG11201501183VA (uk)
TN (1) TN2015000045A1 (uk)
TW (1) TW201412720A (uk)
UA (1) UA112488C2 (uk)
WO (1) WO2014027112A1 (uk)
ZA (1) ZA201501078B (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2015121413A1 (en) * 2014-02-14 2015-08-20 Aicuris Gmbh & Co. Kg New active pharmaceutical ingredient combinations with compounds based on tri(hetero)aryl pyrazoles
EP3263567A1 (en) * 2016-07-01 2018-01-03 AiCuris Anti-infective Cures GmbH Carboxamide-substituted pyrazoles and tri(hetero)aryl-pyrazoles for use in methods of treating and / or preventing cardiovascular diseases and / or comorbidities thereof
MX2020010433A (es) * 2018-04-04 2020-10-28 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6277847B1 (en) 1999-04-02 2001-08-21 Fmc Corporation Herbicidal isoindolinonyl-and 3,4-dihydroisoquinolonyl-substituted heterocycles
DE60235114D1 (de) 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
BR0316332A (pt) 2002-12-02 2005-09-27 Astellas Pharma Inc Composto pirazólico, composição farmacêutica e agente analgésico contendo o mesmo, processo para sua preparação e seu uso e pacote comercial
DE602004028800D1 (en) 2003-02-07 2010-10-07 Daiichi Sankyo Co Ltd Pyrazolderivat
ATE440085T1 (de) 2004-02-20 2009-09-15 Astrazeneca Ab 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
CN1938273B (zh) 2004-03-26 2011-12-14 霍夫曼-拉罗奇有限公司 四氢咔唑类及衍生物
JPWO2006004027A1 (ja) 2004-07-01 2008-04-24 第一製薬株式会社 ピラゾール誘導体
GB0417910D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
ES2326723B1 (es) 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazol sustituidos y combinaciones de los mismos para el tratamiento del sindrome metabolico.
EP1743637A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
GB0516661D0 (en) 2005-08-13 2005-09-21 Astrazeneca Ab Therapeutic agents
EA015034B1 (ru) 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
EP1957076A2 (en) 2005-11-29 2008-08-20 Merck & Co., Inc. Thiazole derivatives as cxcr3 receptor modulators
JP2009518298A (ja) 2005-12-01 2009-05-07 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療に有用な尿素化合物
EP2051966A2 (en) 2006-08-09 2009-04-29 Pfizer Products Inc. Heterocycles useful as inhibitors of carbonic anhydrase
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
EP2217602B1 (en) 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
KR101259240B1 (ko) 2008-02-18 2013-04-29 시에나 바이오테크 에스.피.에이. 4,5-다이하이드로-옥사졸-2-일 아민 유도체
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EA020564B1 (ru) 2009-09-17 2014-12-30 Янссен Фармацевтика Нв Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины
MX2012005518A (es) 2009-11-13 2012-06-19 Merck Serono Sa Derivados de pirazol amina triciclica.
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US20130203756A1 (en) 2010-10-29 2013-08-08 Jamie L. Bunda Isoindoline pde10 inhibitors
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2015121413A1 (en) 2014-02-14 2015-08-20 Aicuris Gmbh & Co. Kg New active pharmaceutical ingredient combinations with compounds based on tri(hetero)aryl pyrazoles

Also Published As

Publication number Publication date
SG11201501183VA (en) 2015-05-28
PH12015500322A1 (en) 2015-03-30
NZ704727A (en) 2016-07-29
US20150203500A1 (en) 2015-07-23
CN104684913A (zh) 2015-06-03
BR112015003115A2 (pt) 2017-07-04
CA2881997A1 (en) 2014-02-20
CN104684913B (zh) 2016-11-23
EP2885300A1 (de) 2015-06-24
KR20150042841A (ko) 2015-04-21
TN2015000045A1 (en) 2016-06-29
CU20150015A7 (es) 2015-11-27
TW201412720A (zh) 2014-04-01
ZA201501078B (en) 2017-11-29
PE20150869A1 (es) 2015-05-27
DE102012016908A1 (de) 2014-02-20
AR092145A1 (es) 2015-03-25
JP2015524835A (ja) 2015-08-27
US9249148B2 (en) 2016-02-02
CL2015000362A1 (es) 2015-07-10
WO2014027112A1 (de) 2014-02-20
PH12015500322B1 (en) 2019-03-25
MA37928A1 (fr) 2017-11-30
MX2015002046A (es) 2015-06-05
IL237298A0 (en) 2015-04-30
AP2015008325A0 (en) 2015-03-31
EA201500232A1 (ru) 2015-07-30
AU2013303993A1 (en) 2015-03-12
HK1212327A1 (en) 2016-06-10

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
EA201591166A1 (ru) Ингибиторы аутотаксина
MX392130B (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
CL2016001895A1 (es) Compuestos
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
UY35747A (es) Derivados sustituidos de fenilalanina
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1